Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery (TOPS-MRSA)

Bay Pines VA Healthcare System

Status and phase

Withdrawn

Phase 2

Conditions

Methicillin-resistant Staphylococcus Aureus

Orthopedic Procedures

Treatments

Drug: Altabax (retapamulin)

Drug: Placebo

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT00903279

TOPS2009

Details and patient eligibility

About

The investigators anticipate that utilization of retapamulin preoperatively will eliminate MRSA colonization among patients who are colonized in their nares.

Full description

Enhanced characterization of MRSA strains carried by patients and their eradication prior to surgery will significantly reduce healthcare costs to the VA by reducing the number of MRSA positive patients who need to be isolated and or closely monitored, and allow healthcare providers to better predict the patient's requirements. In addition, the application of molecular methods will facilitate faster tracking of MRSA postoperative infections.

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients who are admitted for an orthopedic surgical procedure
All patients will be screened and admitted to the study prior to surgery regardless of eventual culture results for MRSA

Exclusion criteria

Pregnancy
Serious systemic illness due to renal, cardiac or hepatic disease
Inability to complete follow-up assessments
Allergy or intolerance to retapamulin
BMI > 30
Uncontrolled diabetes, severe anemia, thrombocytopenia or an underlying hematopoietic disorder or malignancy
Patients with serious life-threatening illnesses and those with terminal illness not expected to survive for two years or more will not be enrolled
Antibiotics administered during the course of the study will be recorded (name, dose and dates)